PMC:7324763 / 72982-73497 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1167","span":{"begin":0,"end":4},"obj":"PR:000009196"},{"id":"T1168","span":{"begin":7,"end":17},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T1169","span":{"begin":80,"end":88},"obj":"SP_7"},{"id":"T1170","span":{"begin":107,"end":118},"obj":"DG_41"},{"id":"T1171","span":{"begin":191,"end":195},"obj":"PR:000001393"},{"id":"T1172","span":{"begin":273,"end":284},"obj":"GO:0072583"},{"id":"T1173","span":{"begin":402,"end":413},"obj":"DG_41"},{"id":"T1174","span":{"begin":497,"end":505},"obj":"SP_7"},{"id":"T91493","span":{"begin":0,"end":4},"obj":"PR:000009196"},{"id":"T58584","span":{"begin":7,"end":17},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T50670","span":{"begin":80,"end":88},"obj":"SP_7"},{"id":"T22229","span":{"begin":107,"end":118},"obj":"DG_41"},{"id":"T68856","span":{"begin":191,"end":195},"obj":"PR:000001393"},{"id":"T24099","span":{"begin":273,"end":284},"obj":"GO:0072583"},{"id":"T60677","span":{"begin":402,"end":413},"obj":"DG_41"},{"id":"T73273","span":{"begin":497,"end":505},"obj":"SP_7"}],"text":"Jak1/2 inhibitors (JAKi) are also undergoing clinical trials in moderate-severe COVID-19 patients, such as baricitinib (NCT04320277). In addition to their ability to impede the production of IL-6, thus curb the excessive inflammation, they may also block clathrin mediated endocytosis–indicating a dual role for JAKi (241). However, JAKi can also lead to the transient increase in NK cells as shown in baricitinib treated Rheumatoid Arthritis patients (250), which could be detrimental for severe COVID-19 patients."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T861","span":{"begin":191,"end":193},"obj":"Body_part"},{"id":"T862","span":{"begin":255,"end":263},"obj":"Body_part"},{"id":"T863","span":{"begin":381,"end":389},"obj":"Body_part"},{"id":"T864","span":{"begin":384,"end":389},"obj":"Body_part"}],"attributes":[{"id":"A861","pred":"fma_id","subj":"T861","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A862","pred":"fma_id","subj":"T862","obj":"http://purl.org/sig/ont/fma/fma62262"},{"id":"A863","pred":"fma_id","subj":"T863","obj":"http://purl.org/sig/ont/fma/fma63147"},{"id":"A864","pred":"fma_id","subj":"T864","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Jak1/2 inhibitors (JAKi) are also undergoing clinical trials in moderate-severe COVID-19 patients, such as baricitinib (NCT04320277). In addition to their ability to impede the production of IL-6, thus curb the excessive inflammation, they may also block clathrin mediated endocytosis–indicating a dual role for JAKi (241). However, JAKi can also lead to the transient increase in NK cells as shown in baricitinib treated Rheumatoid Arthritis patients (250), which could be detrimental for severe COVID-19 patients."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T503","span":{"begin":80,"end":88},"obj":"Disease"},{"id":"T504","span":{"begin":221,"end":233},"obj":"Disease"},{"id":"T505","span":{"begin":422,"end":442},"obj":"Disease"},{"id":"T506","span":{"begin":497,"end":505},"obj":"Disease"}],"attributes":[{"id":"A503","pred":"mondo_id","subj":"T503","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A504","pred":"mondo_id","subj":"T504","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A505","pred":"mondo_id","subj":"T505","obj":"http://purl.obolibrary.org/obo/MONDO_0008383"},{"id":"A506","pred":"mondo_id","subj":"T506","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Jak1/2 inhibitors (JAKi) are also undergoing clinical trials in moderate-severe COVID-19 patients, such as baricitinib (NCT04320277). In addition to their ability to impede the production of IL-6, thus curb the excessive inflammation, they may also block clathrin mediated endocytosis–indicating a dual role for JAKi (241). However, JAKi can also lead to the transient increase in NK cells as shown in baricitinib treated Rheumatoid Arthritis patients (250), which could be detrimental for severe COVID-19 patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T895","span":{"begin":296,"end":297},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T896","span":{"begin":381,"end":389},"obj":"http://purl.obolibrary.org/obo/CL_0000623"}],"text":"Jak1/2 inhibitors (JAKi) are also undergoing clinical trials in moderate-severe COVID-19 patients, such as baricitinib (NCT04320277). In addition to their ability to impede the production of IL-6, thus curb the excessive inflammation, they may also block clathrin mediated endocytosis–indicating a dual role for JAKi (241). However, JAKi can also lead to the transient increase in NK cells as shown in baricitinib treated Rheumatoid Arthritis patients (250), which could be detrimental for severe COVID-19 patients."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4327","span":{"begin":7,"end":17},"obj":"Chemical"},{"id":"T96858","span":{"begin":191,"end":193},"obj":"Chemical"}],"attributes":[{"id":"A59947","pred":"chebi_id","subj":"T4327","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A71063","pred":"chebi_id","subj":"T96858","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A65955","pred":"chebi_id","subj":"T96858","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"Jak1/2 inhibitors (JAKi) are also undergoing clinical trials in moderate-severe COVID-19 patients, such as baricitinib (NCT04320277). In addition to their ability to impede the production of IL-6, thus curb the excessive inflammation, they may also block clathrin mediated endocytosis–indicating a dual role for JAKi (241). However, JAKi can also lead to the transient increase in NK cells as shown in baricitinib treated Rheumatoid Arthritis patients (250), which could be detrimental for severe COVID-19 patients."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2037","span":{"begin":0,"end":6},"obj":"Gene"},{"id":"2038","span":{"begin":191,"end":195},"obj":"Gene"},{"id":"2039","span":{"begin":89,"end":97},"obj":"Species"},{"id":"2040","span":{"begin":443,"end":451},"obj":"Species"},{"id":"2041","span":{"begin":506,"end":514},"obj":"Species"},{"id":"2042","span":{"begin":107,"end":118},"obj":"Chemical"},{"id":"2043","span":{"begin":402,"end":413},"obj":"Chemical"},{"id":"2044","span":{"begin":80,"end":88},"obj":"Disease"},{"id":"2045","span":{"begin":221,"end":233},"obj":"Disease"},{"id":"2046","span":{"begin":422,"end":442},"obj":"Disease"},{"id":"2047","span":{"begin":497,"end":505},"obj":"Disease"}],"attributes":[{"id":"A2037","pred":"tao:has_database_id","subj":"2037","obj":"Gene:3716"},{"id":"A2038","pred":"tao:has_database_id","subj":"2038","obj":"Gene:3569"},{"id":"A2039","pred":"tao:has_database_id","subj":"2039","obj":"Tax:9606"},{"id":"A2040","pred":"tao:has_database_id","subj":"2040","obj":"Tax:9606"},{"id":"A2041","pred":"tao:has_database_id","subj":"2041","obj":"Tax:9606"},{"id":"A2042","pred":"tao:has_database_id","subj":"2042","obj":"MESH:C000596027"},{"id":"A2043","pred":"tao:has_database_id","subj":"2043","obj":"MESH:C000596027"},{"id":"A2044","pred":"tao:has_database_id","subj":"2044","obj":"MESH:C000657245"},{"id":"A2045","pred":"tao:has_database_id","subj":"2045","obj":"MESH:D007249"},{"id":"A2046","pred":"tao:has_database_id","subj":"2046","obj":"MESH:D001172"},{"id":"A2047","pred":"tao:has_database_id","subj":"2047","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Jak1/2 inhibitors (JAKi) are also undergoing clinical trials in moderate-severe COVID-19 patients, such as baricitinib (NCT04320277). In addition to their ability to impede the production of IL-6, thus curb the excessive inflammation, they may also block clathrin mediated endocytosis–indicating a dual role for JAKi (241). However, JAKi can also lead to the transient increase in NK cells as shown in baricitinib treated Rheumatoid Arthritis patients (250), which could be detrimental for severe COVID-19 patients."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T107","span":{"begin":422,"end":442},"obj":"Phenotype"}],"attributes":[{"id":"A107","pred":"hp_id","subj":"T107","obj":"http://purl.obolibrary.org/obo/HP_0001370"}],"text":"Jak1/2 inhibitors (JAKi) are also undergoing clinical trials in moderate-severe COVID-19 patients, such as baricitinib (NCT04320277). In addition to their ability to impede the production of IL-6, thus curb the excessive inflammation, they may also block clathrin mediated endocytosis–indicating a dual role for JAKi (241). However, JAKi can also lead to the transient increase in NK cells as shown in baricitinib treated Rheumatoid Arthritis patients (250), which could be detrimental for severe COVID-19 patients."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T172","span":{"begin":221,"end":233},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T173","span":{"begin":255,"end":284},"obj":"http://purl.obolibrary.org/obo/GO_0072583"},{"id":"T174","span":{"begin":273,"end":284},"obj":"http://purl.obolibrary.org/obo/GO_0006897"}],"text":"Jak1/2 inhibitors (JAKi) are also undergoing clinical trials in moderate-severe COVID-19 patients, such as baricitinib (NCT04320277). In addition to their ability to impede the production of IL-6, thus curb the excessive inflammation, they may also block clathrin mediated endocytosis–indicating a dual role for JAKi (241). However, JAKi can also lead to the transient increase in NK cells as shown in baricitinib treated Rheumatoid Arthritis patients (250), which could be detrimental for severe COVID-19 patients."}

{"project":"MyTest","denotations":[{"id":"32655581-32385052-34771842","span":{"begin":318,"end":321},"obj":"32385052"},{"id":"32655581-30058112-34771843","span":{"begin":453,"end":456},"obj":"30058112"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Jak1/2 inhibitors (JAKi) are also undergoing clinical trials in moderate-severe COVID-19 patients, such as baricitinib (NCT04320277). In addition to their ability to impede the production of IL-6, thus curb the excessive inflammation, they may also block clathrin mediated endocytosis–indicating a dual role for JAKi (241). However, JAKi can also lead to the transient increase in NK cells as shown in baricitinib treated Rheumatoid Arthritis patients (250), which could be detrimental for severe COVID-19 patients."}

{"project":"TEST0","denotations":[{"id":"32655581-184-191-3171415","span":{"begin":318,"end":321},"obj":"[\"32385052\"]"},{"id":"32655581-129-136-3171416","span":{"begin":453,"end":456},"obj":"[\"30058112\"]"}],"text":"Jak1/2 inhibitors (JAKi) are also undergoing clinical trials in moderate-severe COVID-19 patients, such as baricitinib (NCT04320277). In addition to their ability to impede the production of IL-6, thus curb the excessive inflammation, they may also block clathrin mediated endocytosis–indicating a dual role for JAKi (241). However, JAKi can also lead to the transient increase in NK cells as shown in baricitinib treated Rheumatoid Arthritis patients (250), which could be detrimental for severe COVID-19 patients."}

{"project":"2_test","denotations":[{"id":"32655581-32385052-34771842","span":{"begin":318,"end":321},"obj":"32385052"},{"id":"32655581-30058112-34771843","span":{"begin":453,"end":456},"obj":"30058112"}],"text":"Jak1/2 inhibitors (JAKi) are also undergoing clinical trials in moderate-severe COVID-19 patients, such as baricitinib (NCT04320277). In addition to their ability to impede the production of IL-6, thus curb the excessive inflammation, they may also block clathrin mediated endocytosis–indicating a dual role for JAKi (241). However, JAKi can also lead to the transient increase in NK cells as shown in baricitinib treated Rheumatoid Arthritis patients (250), which could be detrimental for severe COVID-19 patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T440","span":{"begin":0,"end":133},"obj":"Sentence"},{"id":"T441","span":{"begin":134,"end":323},"obj":"Sentence"},{"id":"T442","span":{"begin":324,"end":515},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Jak1/2 inhibitors (JAKi) are also undergoing clinical trials in moderate-severe COVID-19 patients, such as baricitinib (NCT04320277). In addition to their ability to impede the production of IL-6, thus curb the excessive inflammation, they may also block clathrin mediated endocytosis–indicating a dual role for JAKi (241). However, JAKi can also lead to the transient increase in NK cells as shown in baricitinib treated Rheumatoid Arthritis patients (250), which could be detrimental for severe COVID-19 patients."}